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See Covering the Cover synopsis on page 5.BACKGROUND & AIMS: We investigated mechanisms of
hepatic stellate cell (HSC) activation, which contributes
to liver fibrogenesis. We aimed to determine whether
activated HSCs increase glycolysis, which is regulated
by 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3
(PFKFB3), and whether this pathway might serve as a
therapeutic target. METHODS: We performed studies with
primary mouse HSCs, human LX2 HSCs, human cirrhotic
liver tissues, rats and mice with liver fibrosis (due to bile
duct ligation [BDL] or administration of carbon tetrachlo-
ride), and CPEB4-knockout mice. Glycolysis was inhibited in
cells and mice by administration of a small molecule
antagonist of PFKFB3 (3-[3-pyridinyl]-1-[4-pyridinyl]-2-
propen-1-one [3PO]). Cells were transfected with small
interfering RNAs that knock down PFKFB3 or CPEB4.
RESULTS: Up-regulation of PFKFB3 protein and increased
glycolysis were early and sustained events during HSC
activation and accompanied by increased expression ofmarkers of fibrogenesis; incubation of HSCs with 3PO or
knockdown of PFKFB3 reduced their activation and prolif-
eration. Mice with liver fibrosis after BDL had increased
hepatic PFKFB3; injection of 3PO immediately after the
surgery prevented HSC activation and reduced the severity
of liver fibrosis compared with mice given vehicle. Levels of
PFKFB3 protein were increased in fibrotic liver tissues from
patients compared with non-fibrotic liver. Up-regulation of
PFKFB3 in activated HSCs did not occur via increased
transcription, but instead via binding of CPEB4 to cyto-
plasmic polyadenylation elements within the 3’-untranslated
regions of PFKFB3 messenger RNA. Knockdown of CPEB4 in
LX2 HSCs prevented PFKFB3 overexpression and cell acti-
vation. Livers from CPEB4-knockout had decreased PFKFB3
and fibrosis after BDL or administration of carbon tetra-
chloride compared with wild-type mice. CONCLUSIONS:
Fibrotic liver tissues from patients and rodents (mice and rats)
have increased levels of PFKFB3 and glycolysis, which are
essential for activation of HSCs. Increased expression of PFKFB3
is mediated by binding of CPEB4 to its untranslated messenger
RNA. Inhibition or knockdown of CPEB4 or PFKFB3 prevents
HSC activation and fibrogenesis in livers of mice.
WHAT YOU NEED TO KNOW
BACKGROUND AND CONTEXT
Little is known about mechanisms of hepatic stellate cell
(HSC) activation, which contributes to liver fibrogenesis.
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hronic liver diseases are highly prevalent and asso-NEW FINDINGS
Fibrotic liver tissues from patients and mice have
increased levels of PFKFB3, which promotes glycolysis,
and activation of HSCs. Increased expression of
PFKFB3 is mediated by binding of CPEB4 to its
untranslated mRNA. Inhibition or knockdown of CPEB4
or PFKFB3 prevents HSC activation and fibrogenesis in
livers of mice.
LIMITATIONS
This study was performed using human cells and tissues
and mice. Further studies are needed in humans.
IMPACT
Strategies to inhibit glycolysis pathways, by targeting the
CPEB4-PFKFB3 circuit, in activated HSCs might be
developed for treatment or prevention of liver fibrosis.
Abbreviations used in this paper: BDL, bile duct ligation; CCl4, carbon
tetrachloride; CPEB, cytoplasmic polyadenylation element binding pro-
tein; DMSO, dimethyl sulfoxide; F2,6BP, fructose-2,6-bisphosphate; HSC,
hepatic stellate cell; mRNA, messenger RNA; PDGF, platelet-derived
growth factor; PFKFB3, 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase-3; 3PO, 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one;
shRNA, short hairpin RNA; siRNA, small interfering RNA; aSMA, alpha-
smooth muscle actin; TGFb, transforming growth factor-beta; WT, wild-
type.Cciated with a high and dramatically increased
burden worldwide.1 Despite that, development of new
therapeutics remains stagnant. Liver transplantation
currently represents the only chance of long-term survival
for patients with chronic liver disease, but the availability of
appropriate donor tissue is limited, and the procedure is
very expensive, necessitating a search for alternatives.
Upon liver injury, activation and transdifferentiation of
hepatic stellate cells (HSCs) into scar-forming myofibro-
blasts is among the first responses detectable at the site of
damage.2 These cells drive a wound-healing response that
relies on the deposition of collagen-rich extracellular
matrix to maintain tissue integrity. This transient
response must be tightly controlled, as it otherwise be-
comes persistent and leads to excessive matrix accumu-
lation and fibrosis. This is what happens when facing
excessive cellular stress, such as in chronic liver injury.
Exacerbated fibrosis impairs normal liver function and
acts as a precursor to cirrhosis, eventually leading to liver
failure and death.3,4 Understanding the molecular bases of
HSC activation is therefore essential to define novel and
more efficient targets of antifibrotic therapy to reduce
incidence and morbidity and mortality of the people
suffering from chronic liver disease.
The myofibroblastic phenotype of activated HSCs is
characterized by increased proliferation and matrix pro-
duction and secretion.4 To cope with these highly ener-
getically demanding processes, it is reasonable to assume
that activated HSCs can exhibit augmented aerobic
glycolysis as an additional bioenergetic and biosynthetic
supply, even in oxygen-rich conditions, similarly to the
observed in many cancer cells,5–7 and other non-
malignant proliferating cells.8–10 In this regard, previous
studies have appreciated the relationship among aerobic
glycolysis (conversion of glucose to lactate), gluta-
minolysis (conversion of glutamine to a-ketoglutarate),
and fibrogenesis.11,12 Deciphering the molecular mecha-
nisms underpinning the metabolic reprogramming in HSCs
can reveal potential targets suitable for therapeutic
intervention. A major driver of glycolysis is 6-
phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3
(PFKFB3),13 which produces fructose-2,6-bisphosphate
(F2,6BP), the most potent allosteric activator of the
glycolytic rate-limiting enzyme phosphofructokinase-1
(PFK1).14 Therefore, we investigated the impact of
PFKFB3 on the activation and fibrogenic behavior of HSCs,
the molecular mechanisms behind this process, and the
potential utility of targeting this enzyme as a new anti-
fibrotic strategy.Most current article
© 2020 by the AGA Institute. Published by Elsevier Inc. This is an open




A detailed description of the Materials and Methods can be
found in the Supplementary Material.Primary Mouse Hepatic Stellate Cell Isolation and
Culture
Mouse HSCs were isolated from adult BALB/c mice by
retrograde pronase-collagenase liver perfusion and density
centrifugation.15 Perfusion through inferior vena cava was
initiated with 15 mL of 190 mg/L EGTA solution. Portal vein
was cut and vena cava clamped above the diaphragm to ensure
correct liver perfusion. Then, perfusion continued with 25 mL
of 0.4 mg/mL pronase solution and, finally, 35 mL of 0.1 U/mL
collagenase solution. The liver was removed, minced, and
incubated (10–20 minutes, 40C, under agitation) in pronase/
collagenase solution containing 1% (vol/vol) DNase. The
resulting dispersed cell suspension was filtered through 70-mm
cell strainer and centrifuged (50g, 5 minutes). HSCs were
separated by Histodenz density gradient centrifugation (Sigma,
St Louis, MO) and culture-activated on 12-well Nunc plates
(Thermo-Fisher, Waltham, MA) or 18-mm coverslips in Dul-
becco’s modified Eagle medium containing 10% fetal bovine
serum, 100 U/mL penicillin, 100 mg/mL streptomycin, and 2
mM L-glutamine.
Human Hepatic Stellate Cell Line and Culture
LX2 human HSC line (Merck, Madrid, Spain; SCC064) was
generated by immortalization of primary human HSCs with the
July 2020 CPEB4-PFKFB3 Circuit in Liver Fibrosis 275SV40 large T antigen.16 LX2 cells were cultured in high-glucose
Dulbecco’s modified Eagle medium containing 10% fetal bovine
serum, 100 U/mL penicillin, 100 mg/mL streptomycin, and 2
mM L-glutamine.Measurement of Fructose-2,6-Bisphosphate
Intracellular F2,6BP content was measured in LX2 cells
using the Van Schaftingen’s method.17 LX2 cells were cultured
for 3 days on a medium containing 7.5 mM 3PO or vehicle
(dimethyl sulfoxide [DMSO]). Then, LX2 cells were homoge-
nized in extraction buffer containing 0.1 M NaOH and 0.1%
Triton X-100. The resulting mixture was heated for 5 minutes
at 80C. After cooling, cells were centrifuged and supernatant
neutralized with a solution containing 10 mM HEPES in acetic
acid. The mixture was centrifuged and F2,6BP content
measured in the supernatant using a coupled enzyme
reaction.17Statistical Analysis
Data are shown as mean ± SEM. Results that were normally
distributed (P > .05 from Kolmogorov-Smirnov test) were
compared with parametric statistical procedures (Student t test
and analysis of variance followed by Bonferroni test for mul-
tiple comparisons). Non-normally distributed results were
compared with nonparametric tests (Kruskal-Wallis 1-way
analysis of variance and Mann-Whitney U test). Significance
















The Protein Expression of the Key Glycolytic
Enzyme PFKFB3 Is Up-Regulated During Hepatic
Stellate Cell Activation
The study began characterizing the expression pattern of
the critical glycolytic enzyme PFKFB3 during the activation
of HSCs, the principle cells responsible for liver fibrosis. To
this end, we utilized freshly isolated mouse primary HSCs
undergoing culture-induced activation and trans-
differentiation from a quiescent to a myofibroblastic
phenotype (Figure 1A). We found that PFKFB3 expression
rapidly switched on during the myofibroblastic differentia-
tion, within 24 hours after plating, as demonstrated by co-
immunofluorescence with the typical myofibroblastic
marker alpha-smooth muscle actin (aSMA) (Figure 1B).
These results were confirmed in the human LX2 HSC line
(Figure 1A), which has been extensively characterized and
retains key features of human activated HSCs.16 We cultured
LX2 cells for up to 7 days on plastic surfaces of cell culture
dishes as a surrogate for the molecular changes that occur
during HSCs in the injured liver. We comparatively analyzed
the expression of PFKFB3 and the myofibroblastic markers
aSMA , platelet-derived growth factor (PDGF), PDGF re-
ceptor-b, and collagen type I at different times by immu-
noblot analysis. We found that PFKFB3 protein
up-regulation was an early and sustained event during
HSC activation that was accompanied by increased expres-
sion of fibrogenic markers (Figure 1C). These findingssupport the idea that HSCs undergo a PFKFB3-regulated
glycolytic reprogramming during cell activation.
PFKFB3 Blockade Attenuates Glycolysis in
Hepatic Stellate Cells
To determine the biological consequences of the
enhanced glycolysis, we studied the effects of the small
molecule inhibitor of PFKFB3, 3-(3-pyridinyl)-1-(4-
pyridinyl)-2-propen-1-one (3PO),18 on HSCs (Figure 1D).
LX2 cells were plated for 3 days on a medium containing a
low dose of 3PO or vehicle (DMSO). Inhibition of PFKFB3
enzymatic activity in LX2 cells resulted in a significant 51%
reduction in F2,6BP (the product of the reaction catalyzed
by PFKFB3 and an allosteric activator of PFK1 and surrogate
marker for the glycolytic rate) (Figure 1D), without causing
cell death, in agreement with previous studies using 3PO in
other cell types.19
PFKFB3 Blockade Reduces Hepatic Stellate Cell
Activation and Profibrogenic Phenotype In Vitro
Next, we evaluated the effects of inhibition of PFKFB3-
driven glycolysis on primary mouse HSCs. We found that
morphological changes typically associated with HSC dif-
ferentiation were blocked by the glycolytic blocker 3PO
(Figure 1E). Thus, at 2 hours, before any treatment, there
was a homogeneous population of cells containing lipid
droplets. Within 1 day of seeding, primary mouse HSCs
treated with vehicle adhered and began to put out fine
cellular processes on the tissue culture plastic surface, as
shown by phase-contrast light microscopy (Figure 1E).
After 4 days, cells became larger and more myofibroblast-
like in their appearance, with long cytoplasmic processes
branching out from the stellate cell body and an expanded
and flattened shape (Figure 1E). These activated HSCs also
progressively lost their cytoplasmic lipid droplets
(Figure 1E, refringent vesicles; and Figure 1F, Oil Red-O
staining), which serve in quiescent cells as a storage
compartment for vitamin A. Notably, 3PO treatment pre-
vented the culture-induced activation of primary mouse
HSCs, such that the phenotypic appearance of treated cells
closely resembled that of freshly isolated quiescent cells,
with a rounded morphology and abundant lipid droplets
(Figure 1E and F). In addition, the typical positivity for the
contractile protein aSMA, a reliable marker of the
phenotypic transformation of HSCs into myofibroblast-like
cells, was markedly decreased in 3PO-treated cells, both at
messenger RNA (mRNA) (Figure 1G; reverse transcription
polymerase chain reaction) and protein levels (Figure 1H;
immunofluorescence), compared with vehicle-treated
cells.
To further interrogate our results, we studied human
LX2 cells. After 1, 3, or 6 days in culture, LX2 cells were
exposed to low concentrations of 3PO or vehicle (DMSO)
and then harvested 3 days later. We found that 3PO mark-
edly reduced expression of core proteins in HSC activation
and fibrogenesis, including aSMA, PDGF, its receptor
PDGFR-b, and vascular endothelial growth factor, as
assessed by immunoblotting (Figure 2A). The




LIVERoverexpression of PFKFB3 observed with time in LX2 cells
was also down-regulated by 3PO (Figure 2A), reflecting the
decrease in glycolysis caused by the PFKFB3 blocker.
Similar results were also observed in primary mouse HSCs,as demonstrated by immunofluorescence (Figure 2B), sug-
gesting that the antifibrotic properties of PFKFB3 inhibition
are likely conserved across mammalian species. Inhibition
of PFKFB3-driven glycolysis also influenced the proliferative
July 2020 CPEB4-PFKFB3 Circuit in Liver Fibrosis 277capacity of HSCs, supporting the well-established concept
that glycolytic reprogramming leads to a metabolic state
ideal for the proliferation and sustenance of rapidly multi-
plying cells.20–22 Thus, 3PO dose-dependently reduced the
rate of cell proliferation observed upon culture activation, as
demonstrated by measuring the incorporation of 5’-bromo-
2’-deoxyuridine to the DNA of LX2 cells by flow cytometry
(Figure 2C–E), and counting cell number (Figure 2F). These
results together indicate that HSCs rely heavily on PFKFB3-
dependent glycolytic reprogramming to fuel cell activation,
proliferation, and fibrogenesis.
To further confirm the findings with 3PO, we applied a
different strategy to decrease PFKFB3 activity using small
interfering RNAs (siRNA) specifically silencing the PFKFB3
gene. Human LX2 cells were incubated for 3 days (a time
point at which cells are well activated and PFKFB3 protein
is significantly overexpressed) (Figure 2A), and then trans-
fected with PFKFB3 siRNAs or control siRNAs. Assays were
conducted 24 or 96 hours later (Figure 2G). We found that
only when PFKFB3 protein expression was efficiently
reduced (at 96 hours post-transfection), the expression of
aSMA protein was also effectively down-regulated
(Figure 2H), further demonstrating the essential require-
ment of PFKFB3 up-regulation for initiation and perpetua-















PFKFB3 Protein Expression Is Elevated in
Fibrotic Human and Rodent Livers
To further underscore the importance of PFKFB3 as
regulator of liver fibrosis, we investigated its level of
expression in human liver. We found that the expression of
PFKFB3 protein was higher in the liver from patients with
hepatitis C virus–related cirrhosis than in healthy tissue, as
demonstrated by immunoblotting (Figure 3A) and by
immunohistochemistry (Figure 3B). We next analyzed the
expression profile of PFKFB3 protein in a well-established
experimental model in rodents, where fibrosis is produced
by bile duct ligation (BDL). Immunoblot analysis using livers
from BDL rats at different time points after fibrosis induc-
tion (days 1, 3, 7, 14, and 28), and from sham-operated
control rats, demonstrated gradual increase in PFKFB3
protein expression levels after BDL compared with normal
livers (Figure 3C). Of note, this PFKFB3 up-regulation was
observed in the nucleus as well as in the cytoplasm=
Figure 1. PFKFB3 protein expression is up-regulated during
glycolysis in HSCs. (A) In vitro studies were conducted in HSCs
line. (B) Co-immunofluorescence for PFKFB3 (red) and aSMA (g
Diamidino-2-phenylindole–stained nuclei (DAPI) (blue). Scale ba
fication for the indicated proteins in LX2 cells. (D) Schematic re
glycolytic intermediate fructose-6-phosphate (F6P) into F2,6B
enzyme PFK1, thereby accelerating glycolysis. The inhibitor o
content in LX2 cells compared with vehicle-treated cells (DMSO)
in culture, before any treatment, and also cultured for 1, 2, and
mm. (F) Visualization of lipid droplets by Oil Red-O staining in co
expression in control and 15 mM 3PO-treated mouse HSCs. (H)
3PO-treated mouse HSCs. DAPI-stained nuclei (blue). Scale ba(Figure 3C), further suggesting a possible translocation of
PFKFB3 to the nuclei to regulate cell cycle and activate cell
proliferation (Figure 2C–F). Nuclear PFKFB3 expression was
also detected in mouse HSC by immunofluorescence
(Figures 1B and 2B). Studies in mouse fibrotic livers further
confirmed these findings (Figure 3D). In both rats and mice,
the overexpression of PFKFB3 protein accompanied the
increase of aSMA and other markers of HSC activation, such
as PDGFR-b and vascular endothelial growth factor
(Figures 3C and D). These results were substantiated by co-
immunofluorescence (Figure 3E) and immunohistochem-
istry (Figure 3F) showing that cells with spindle
morphology, staining positive for both PFKFB3 and aSMA,
accumulated in fibrotic livers surrounding portal tracts.
These results suggest that, as in the in vitro model systems,
changes in the glycolytic enzyme PFKFB3 are linked with
the outgrowth of activated HSC during liver fibrosis in vivo.
These spindle cells were positive for the marker of cell
replication Ki67, implicating that they were proliferating
(Figure 3G). This is expected because it is well known that,
although in physiological conditions HSCs are mitotically
quiescent, they undergo rapid and dramatic increase in
proliferation after BDL.4
To find out more about the spatiotemporal expression
pattern of PFKFB3 and its relationship with the time course
of HSC activation and fibrogenesis in the fibrotic liver, we
performed immunohistochemistry for PFKFB3 and aSMA,
and histological staining with Sirius Red (ie, fibrosis detec-
tion) in consecutive liver sections from sham-operated
control mice or mice subjected to BDL and studied at
different time points thereafter. Although PFKFB3 was
poorly expressed in sham animals, we found it to be
abundant in portal tracts after fibrosis induction, correlating
with aSMA expression and Sirius Red staining (Figure 4A).
Because tissue hypoxia is a common theme in the pathways
leading to PFKFB3 induction and fibrosis progression,2,23,24
we also asked whether PFKFB3 up-regulation in liver
fibrosis correlates with hypoxic areas in vivo. Using the
hypoxia marker pimonidazole hydrochloride (hypoxyp-
robe), which is reductively activated and covalently bound
to macromolecules in cells at low oxygen concentration,24
we detected the typical oxygen gradient of the normal
liver, running from central vein toward portal triads,
following the normal intrahepatic blood flow (Figure 4B).
Upon fibrosis induction, there was a progressive increase inHSC transdifferentiation, and PFKFB3 blockade attenuates
freshly isolated from mice, and in the human LX2 stellate cell
reen) in primary mouse HSCs cultured for 1 and 4 days. 4,6-
r: 25 mm. (C) Immunoblotting and protein expression quanti-
presentation of the glycolytic pathway. PFKFB3 converts the
P, which, in turn, enhances the activity of the rate-limiting
f PFKFB3 enzymatic activity 3PO (7.5 mm) reduces F2,6BP
. (E) Phase-contrastmicrographs of mouse HSCs after 2 hours
4 days in presence or absence of 3PO (15 mm). Scale bar: 50
ntrol and 15 mM 3PO-treated mouse HSCs. (G) aSMA mRNA
aSMA immunocytofluorescence (green) in control and 15 mM
r: 25 mm. *P < .05; **P < .01.
Figure 2. PFKFB3 blockade represses HSC activation and profibrogenic phenotype in vitro. (A) Immunoblotting and protein
expression quantification for the indicated proteins in control and 3PO-treated LX2 cells. Data are mean ± SEM of 2–3 different
experiments. (B) Co-immunocytofluorescence for PFKFB3 (red) and aSMA (green) in control or 3PO-treated mouse HSCs. 4,6-
diamidino-2-phenylindole (DAPI)–stained nuclei (blue). Scale bar: 25 mm. (C) LX2 cellular proliferation measured by flow
cytometric 5’-bromo-2’-deoxyuridine (BrdU) incorporation analysis. (D) Quantification of BrdU plots. (E) BrdU immunofluo-
rescence (red) in control and 3PO-treated LX2 cells. DAPI-stained nuclei (blue). Scale bar: 25 mm. (F) Time course of LX2 cell
proliferation in presence of 3PO or vehicle. *P < .05. (G) Schematic overview of the transfection experiment. (H) Immuno-
blotting for PFKFB3 and aSMA in LX2 cells, cultured for 72 hours, and then transfected with PFKFB3 siRNAs or control
siRNAs. Assays conducted at 24 and 96 hours post-transfection.





July 2020 CPEB4-PFKFB3 Circuit in Liver Fibrosis 279the size of hepatocellular hypoxic areas (Figure 4B),
compatible with the occurrence of liver blood supply
impairment and impaired oxygen delivery to hepatocytes
during fibrosis.24 It is interesting that PFKFB3-positive cellsaccumulated preferentially in regions of the fibrotic liver
exposed to high levels of oxygen or at least normoxic con-
ditions (ie, portal tracts), where pimonidazole immunolab-



















LIVERhypoxic microenvironment surrounding hepatic central
veins (Figure 4B). This nonoverlapping expression pattern
of pimonidazole and PFKFB3 supports that activated HSCs
exhibit an abnormally high glycolytic rate regardless of the
presence of adequate oxygen and is consistent with the
possibility that PFKFB3 overexpression in the fibrotic liver
does not require a locally hypoxic milieu for success.
PFKFB3 Blockade Reduces Fibrogenesis In Vivo
To analyze the impact of targeting PFKFB3-mediated
glycolysis on HSC activation and fibrogenesis in vivo, we
used mice with BDL-induced liver fibrosis, in which hepatic
PFKFB3 expression is up-regulated, as demonstrated in this
study (Figures 3D–F and 4A). Starting immediately after the
initial surgery, the mice were administered either vehicle
(DMSO) or a low dose of 3PO (35 mg/kg, intraperitoneal)
(Figure 4C). There were no significant differences in body
weight (Figure 4D), liver weight (Figure 4E), spleen weight
(Figure 4F), or any apparent adverse side effect in BDL mice
receiving 3PO compared to those treated with DMSO alone.
Interestingly, pharmacological PFKFB3 inhibition by 3PO
markedly prevented the activation of HSCs and the extent of
fibrosis after liver damage, compared with vehicle-treated
BDL mice, as indicated by counting the number of cells
positive for the HSC marker desmin (Figure 4G), immuno-
histochemistry for desmin (Figure 4H), and morphometric
analysis of Sirius Red staining (Figures 4I and J). Because
PFKFB3 overexpression after BDL was not restricted to
HSCs, but also extended to biliary epithelial cells (Figures 3E
and 3F), we determined the effects of PFKFB3 inhibition on
ductular proliferation. Similar numbers of bile ducts were
identified on H&E-stained sections from 3PO- and vehicle-
treated BDL mice (Figures 4I and 4K). Taken together,
these results underscore the importance of HSC glycolysis in
controlling the fibrogenic process and support the potential
utility of 3PO as a novel antifibrotic agent.
The Cytoplasmic Polyadenylation Element
Binding Protein CPEB4 Is Functionally Linked
With PFKFB3 During Hepatic Stellate Cell
Activation
Understanding the molecular mechanisms responsible
for the pathological induction of PFKFB3 during HSC acti-
vation can provide new therapeutic strategies for liver
fibrosis. Interestingly, the progressive up-regulation of
PFKFB3 during HSC activation observed on protein level by=
Figure 3. PFKFB3 protein expression is elevated in fibrotic hum
expression quantification in human healthy human liver and h
staining in cirrhotic human liver sections, showing PFKFB3-posit
mm (left), 50 mm (middle), 25 mm (right). (C) Immunoblotting and
liver at different time points after BDL, and in sham-operated co
Two major PFKFB3 immunoreactive bands were detected, whi
noblotting and protein expression quantification for the indicated
in sham mice. (E) Co-immunofluorescence showing spindle cells
in portal tracts of BDL mice. 4,6-diamidino-2-phenylindole–sta
tochemistry in portal tracts of BDL mouse liver. Scale bar: 50 mm
liver. Scale bar: 25 mm. *P < .05; **P < .01.immunofluorescence (Figure 1B) and immunoblotting
(Figure 1C) was not confirmed on mRNA level, as measured
by reverse transcription polymerase chain reaction
(Figures 5A–C). These results indicate that the over-
expression process does not require de novo transcription
of PFKFB3, raising the possibility that PFKFB3 up-regulation
in this context is modulated through post-transcriptional
mechanisms. Notably, we have found that the 3’-untrans-
lated region of the PFKFB3 mRNA contains a combinatorial
arrangement of a specific cis-acting element named cyto-
plasmic polyadenylation element (CPE) (Figure 5D).25,26
CPEs are U-rich sequences that recruit the CPE-binding
proteins (CPEB) that in turn promote cytoplasmic poly-
adenylation and translational activation.26–35 Therefore, we
postulated that CPEB4-mediated translation could be
required to increase PFKFB3 protein expression and acti-
vate HSCs. In support of this possibility, we found that
CPEB4 protein expression was increased in both human LX2
cells (Figure 5E) and in primary mouse HSCs (Figure 5F),
correlating with PFKFB3 overexpression and HSC activation
(Figure 3C), as demonstrated by immunoblotting and co-
immunofluorescence. CPEB4 up-regulation was linked to
the glycolytic status of HSCs. Thus, when the PFKFB3-
dependent glycolysis of HSCs was inhibited by 3PO, the
overexpression of CPEB4 was attenuated (Figures 5G and
H), suggesting that a molecular circuit composed of CPEB4
and PFKFB3 controls glycolytic reprogramming in HSCs.The RNA Binding Protein CPEB4 Post-
Transcriptionally Regulates PFKFB3 Expression
and Induces an Activated Fibrogenic Phenotype
in Hepatic Stellate Cells
To better define the connection between CPEB4 function
and PFKFB3, we performed RNA-protein co-immunopre-
cipitation studies in LX2 cells (Figure 6A). An antibody
targeting our RNA-binding protein of interest was used to
immunoprecipitate CPEB4 and any interacting molecules
from the HSC lysates. Reverse transcription followed by
polymerase reaction was then used to identify individual
PFKFB3 mRNAs isolated with CPEB4. This is a reliable tool
to study the interaction of CPEB4 to the target PFKFB3
mRNA in HSCs. We found that PFKFB3 transcripts were
enriched in the CPEB4 co-immunoprecipitation compared to
the IgG co-immunoprecipitation (Figure 6B), demonstrating
that PFKFB3 mRNA is indeed a direct target of CPEB4 in
activated HSCs. To corroborate our findings, we usedan and rodent livers. (A) PFKFB3 immunoblotting and protein
epatitis C virus–related cirrhotic liver. (B) PFKFB3 immuno-
ive spindle cells in fibrous septa (arrowheads). Scale bars: 100
protein expression quantification for PFKFB3 and aSMA in rat
ntrol rats. Total, cytosolic, and nuclear fractions were studied.
ch may represent post-translational modifications. (D) Immu-
proteins in mouse liver at different time points after BDL and
(arrowheads) co-expressing PFKFB3 (red), and aSMA (green)
ined nuclei (blue). Scale bar: 50 mm (F) PFKFB3 immunohis-
(G) Ki67 immunohistochemistry in portal tracts of BDL mouse
Figure 4. PFKFB3 blockade attenuates liver fibrosis in vivo. (A) PFKFB3 immunohistochemistry (top), aSMA immunohisto-
chemistry (middle), and Sirius Red histological staining (bottom) in serial liver sections from mice subjected to fibrosis in-
duction by BDL, and from sham-operated control animals. Scale bar: 200 mm. (B) Comparison between PFKFB3
immunohistochemistry and hypoxyprobe immunohistostaining (hypoxic areas stained in brown) in the liver from sham or BDL
rats. Scale bars: 100 mm (PFKFB3), 200 mm (hypoxyprobe). (C) Experimental set-up. (D) Body weight in BDL mice before and
after treatment with 3PO or vehicle. (E) Liver weight in BDL mice treated with 3PO or vehicle. (F) Spleen weight. (G) Quanti-
fication of desmin-positive cells. (H) Desmin immunohistochemistry in the liver from BDL mice treated with 3PO or vehicle and
in sham mice. Scale bar: 100 mm. (I) Sirius Red staining and H&E staining in BDL mouse liver after 3PO or vehicle. Scale bar:
100 mm (Sirius Red), 200 mm (H&E). (J) Sirius Red quantification. *P < .001. (K) Quantification of bile ducts in BDL mice treated
with 3PO or vehicle.
















Figure 5. CPEB4 is functionally linked with PFKFB3 during HSC activation. (A) PFKFB3 mRNA expression in mouse HSCs. (B)
PFKFB3 mRNA expression in LX2 cells. (C) Collagen I mRNA expression in LX2 cells. (D) Schematic representation of PFKFB3
mRNA showing CPE sequences binding CPEB4 in 3’-untranslated region. (E) CPEB4 immunoblotting and protein expression
quantification in LX2 cells. (F) Co-immunofluorescence for CPEB4 (red) and aSMA (green) in mouse HSCs. 4,6-diamidino-2-
phenylindole (DAPI)–stained nuclei (blue). Scale bar: 25 mm. (G) CPEB4 immunoblotting and protein expression quantification
in control or 3PO-treated LX2 cells. Data are mean ± SEM of 2–3 different experiments. (H) Co-immunofluorescence for
CPEB4 (red) and aSMA (green) in control or 3PO-treated mouse HSCs. DAPI-stained nuclei (blue). Scale bar: 25 mm. *P < .05;
**P < .01.





Figure 6. CPEB4 post-transcriptionally regulates PFKFB3 expression and induces an activated fibrogenic phenotype in HSCs. (A)
Schematic diagram of RNA-protein immunoprecipitation method. (B) Reverse transcription polymerase chain reaction detection of
PFKFB3 and glyceraldehyde 3-phosphate dehydrogenase mRNA levels after co-immunoprecipitation with CPEB4 in LX2 cells. (C)
PFKFB3 immunoblotting and protein expression quantification in LX2 cells in presence or absence of the polyadenylation inhibitor
cordycepin (4 and 8 mg/mL). (D) Immunoblotting and protein expression quantification for PFKFB3 and collagen I in LX2 cells in the
presence or absence of cordycepin (4 mg/mL). Data are mean ± SEM of 2–3 different experiments. (E) Immunoblotting and protein
expression quantification for the indicated proteins in LX2 cells transfected with scramble or CPEB4 shRNAs. (F) Soluble collagen
content in LX2 transfected with scramble or CPEB4 shRNAs. (G) Collagen I immunofluorescence (red) in LX2 cells transfected with
scramble or CPEB4 shRNAs. 4,6-diamidino-2-phenylindole–stained nuclei (blue). Scale bar: 25 mm. (H) Immunoblotting and protein
expression quantification for PFKFB3 and aSMA in LX2 cells treated with TGFb (0, 5, and 1 ng/mL) or vehicle. *P < .05.




















LIVERcordycepin (3’-deoxyadenosine), a known inhibitor of CPEB-
dependent polyadenylation.25,36 Because of the 3’-deoxy
moiety, this nucleoside analog acts by blocking poly(A)
elongation. Pretreatment with cordycepin markedly dis-
rupted the up-regulation of PFKFB3 observed in LX2 cells(Figure 6C), leading to reduced collagen I protein expression
(Figure 6D), indicating that polyadenylation is a critical
process for PFKFB3 protein expression in activated HSCs.
To determine the functional impact of the regulation of
PFKFB3 expression by CPEB4, we silenced CPEB4
July 2020 CPEB4-PFKFB3 Circuit in Liver Fibrosis 285expression in LX2 cells using short hairpin RNAs (shRNAs).
We transfected LX2 cells with recombinant lentiviruses
expressing isopropylthio-b-galactoside–inducible shRNAs
against CPEB4, and compared with LX2 cells expressing
control shRNAs. Immunoblotting analysis of these cells
demonstrated the robust and effective depletion of CPEB4
caused by CPEB4 shRNAs (Figure 6E), which attenuated
PFKFB3 expression and, in turn, compromised the ability of
HSCs to activate and produce extracellular matrix proteins,
as demonstrated by the reduction in aSMA (Figure 6E;
immunoblotting) and collagen I expression (Figure 6E–G;
immunoblotting, Sircol soluble collagen assay, and
immunofluorescence).
Because transforming growth factor–beta (TGFb) pro-
motes liver fibrosis by activating HSCs, and TGFb tran-
scriptionally up-regulates PFKFB3 mRNA in cancer cells,37
we determined whether the profibrogenic effects of TGFb
involve PFKFB3 induction. Interestingly, we found that the
dose-dependent activation of LX2 cells caused by TGFb was
not associated with a parallel increase in PFKFB3 expres-
sion (Figure 6H). This finding reinforces the idea that the
mechanism mediating PFKFB3 protein up-regulation is
cellular context–dependent, being, during HSC activation,
















CPEB4 Deficiency in Knockout Mice Prevents
PFKFB3 Up-Regulation and Fibrogenesis After
Bile Duct Ligation and Carbon Tetrachloride
Treatment
To complement the in vitro approach, we generated a
global loss-of-function genetic mouse model (CPEB4KO) to
determine the effects of silencing CPEB4 expression in vivo
on liver fibrogenesis. CPEB4KO mice and their wild-type
(WT) littermates were subjected to BDL to induce liver
fibrosis and studied 14 days later (Figure 7A). CPEB4KO BDL
mice displayed no differences in body weight (Figure 7B),
liver weight (Figure 7C), mean arterial pressure (Figure 7D),
or heart rate (Figure 7E) compared with WT BDL controls.
Spleen weight was decreased by 25% in CPEB4KO BDL mice
compared with WT BDL controls, but the difference was not
statistically significant (Figure 7F). We demonstrated that
CPEB4KO mice have effective CPEB4 depletion in the liver
(Figure 7G). This effect was accompanied by a significant
decrease in PFKFB3 protein expression (Figure 7G), as
found in CPEB4 knockdown HSCs (Figure 6E). These results=
Figure 7. CPEB4 deficiency in knockout mice prevents PFKFB3
(A) CPEB4KO and WT mice were subjected to BDL to induce live
CPEB4KO mice before and after BDL. (C) Liver weight in WT and
(F) Spleen weight. (G) Immunoblotting and protein expression
BDL mice. (H) aSMA immunostaining in the liver from WT and C
and desmin immunostaining in WT and CPEB4KO BDL mice.
CPEB4KO BDL mice. (K) Bile duct quantification in WT and CPE
CCl4 (0.5 mL/g body weight; intraperitoneal injections, twice a w
CCl4-treated WT and CPEB4
KO mice. (N) Liver weight in CCl4
treated WT and CPEB4KO mice. (P) Sirius Red and H&E staining
Sirius Red quantification in CCl4-treated WT and CPEB4
KO mice
treated WT and CPEB4KO mice at 48 hours after the last CCl4demonstrate that PFKFB3 levels are maintained high during
liver fibrosis, owing to CPEB4-dependent translation.
Interestingly, CPEB4KO mice developed less-severe forms of
fibrogenesis after BDL compared with WT animals, as
demonstrated by immunoblotting of fibrillar collagen I
(Figure 7G), aSMA immunoblotting and immunohisto-
chemistry (Figure 7G and 7H), desmin immunohistochem-
istry (Figure 7I), and Sirius Red histologic staining
(Figure 7I and J). Similar to that observed after inhibition of
PFKFB3 enzymatic activity, the number of bile ducts was
not affected by depletion of CPEB4 (Figure 7K), suggesting
that the attenuation of liver fibrosis observed upon CPEB4
silencing was not mediated by interference with a potential
profibrogenic function of biliary epithelial cells.
To further verify that the circuit CPEB4-PFKFB3 acti-
vates fibrogenesis in an HSC-preferential manner, we
induced liver fibrosis in CPEB4KO and WT mice by carbon
tetrachloride (CCl4) (0.5 mL/g body weight; intraperitoneal
injections, 2 times per week for 8 weeks), thus reducing the
ductular proliferation component (Figure 7L). We found no
changes in body weight (Figure 7M) and liver weight
(Figure 7N) comparing CCl4-treated CPEB4
KO and WT mice.
Spleen weight was 20% lower in CCl4-treated CPEB4
KO mice
than in WT controls (Figure 7O), but the difference did not
reach statistical significance. Notably, depletion of CPEB4
significantly reduced fibrogenesis in the CCl4-treated mice
(Figures 7P and Q), compared with CCl4-treated WT ani-
mals. Serum levels of alanine aminotransferase (a trans-
aminase enzyme used as a measure of hepatocyte injury)
were essentially unaltered in CCl4-treated CPEB4
KO and WT
control mice (Figure 7R), verifying that the lower liver
fibrosis observed in CCl4-treated CPEB4
KO was not a
consequence of reduced hepatocellular damage induced by
CCl4. Collectively, these in vivo studies, together with the
aforementioned in vitro studies, indicate that HSCs use the
CPEB4-PFKFB3 axis to generate fibrosis. Obviously, hepatic
fibrosis is a complex phenomenon orchestrated by a
multitude of cells, mediators, and signaling pathways. It is
important to note that, regardless of whether there is a
single cell type (ie, HSCs) involved in the pharmacological
action of 3PO or the CPEB4 targeting, or whether the effects
are potentiated by a potential action on accessory profi-
brogenic cell types (ie, biliary cells), the net effect is a
marked decrease in fibrosis. This is a highly relevant finding
from a therapeutic and translational point of view, consid-
ering that there is an urgent need to develop new anti-
fibrotic strategies.up-regulation and fibrogenesis after BDL and CCl4 treatment.
r fibrosis and studied 14 days later. (B) Body weight in WT and
CPEB4KO BDL mice. (D) Mean arterial pressure. (E) Heart rate.
quantification for the indicated proteins in WT and CPEB4KO
PEB4KO BDL mice. Scale bar: 200 mm. (I) Sirius Red staining
Scale bar: 100 mm. (J) Sirius Red quantification in WT and
B4KO BDL mice. (L) CPEB4KO and WT mice were treated with
eek for 8 weeks) to induce liver fibrosis. (M) Body weight in
-treated WT and CPEB4KO mice. (O) Spleen weight in CCl4-
in CCl4-treated WT and CPEB4
KO mice. Scale bar: 200 mm. (Q)
. (R) Serum alanine aminotransferase levels measured in CCl4-
injection. *P < .05; **P < .01.





Results presented here provide new insights into the
molecular mechanisms of liver fibrogenesis and arouse hope
for developing more effective antifibrotic therapies. Thus, this
work unveils a previously unrecognized post-transcriptional
regulatory circuit in activated HSCs, comprising the critical
glycolytic enzyme PFKFB3 and the RNA-binding protein
CPEB4, which maintains HSCs in fibrotic livers with a higher
glycolytic activity than normal HSCs in healthy livers. This
abnormal glycolytic reprogramming predisposes HSCs to
activation, myofibroblast transdifferentiation, cellular prolif-
eration, and extracellular matrix production and accumula-
tion, resulting in exponentation of liver fibrosis.
Our findings position PFKFB3-dependent glycolysis as a
hallmark of HSC activation in liver fibrosis. PFKFB3 protein
is overexpressed during HSC activation in vitro, both in
human LX2 stellate cells and in freshly isolated mouse HSCs.
The protein expression of PFKFB3 is also consistently
elevated in vivo in the liver of cirrhotic patients, and in
experimental models of fibrosis in rats and mice. This
PFKFB3 up-regulation is a cardinal feature required to
enhance glycolytic flux and induce an activated profibro-
genic phenotype, because PFKFB3 blockade impaired these
changes and reduced matrix production in vitro and in vivo.
Consequently, PFKFB3 inhibition could be an attractive
target for therapeutic inhibition of fibrogenesis. Notably,
based on our studies and previous data by other groups,11,12
dual targeting of glycolysis and glutaminolysis (which
cooperatively control HSC function) may provide an inno-
vative and promising antifibrotic strategy.
Our studies also decipher the regulatory mechanism
behind the up-regulation of PFKFB3 in HSCs, through the
function of the cytoplasmic polyadenylation element bind-
ing protein CPEB4. This RNA-binding protein is an exem-
plary key post-transcriptional regulator,26–35 which is
overexpressed in chronic liver disease and is of paramount
importance for fine-tuning protein synthesis and patholog-
ical cellular phenotypes, as we demonstrated recently.38–40
Our present studies showing that CPEB4 plays an impor-
tant role in HSC activation and fibrogenesis significantly
extend our previous reports and provide an additional node
of interaction between CPEB-mediated post-transcriptional
misregulation and liver disease. Both in human LX2 cells
and primary mouse HSCs, we found that PFKFB3 protein
overexpression was not accompanied by PFKFB3 mRNA up-
regulation, indicating that it was not transcriptionally
derived. Instead, we observed that PFKFB3 protein levels
were maintained high during HSC transdifferentiation,
owing to activation of cytoplasmic polyadenylation and
translation by CPEB4. Thus, CPEB4 protein is up-regulated
early during HSC activation and binds directly to CPE ele-
ments present on the 3’-untranslated region of the PFKFB3
transcript. This favors PFKFB3 mRNA cytoplasmic poly-
adenylation and, in turn, activates translation and generates
high levels of the glycolysis activator PFKFB3. This mecha-
nism does not exclude an additional regulation of PFKFB3
expression. Hence, it is not unusual for key proteins to beregulated at multiple levels, including transcription, trans-
lation, post-translational modifications, and/or protein
degradation.23,24,41 However, in the case of PFKFB3 and its
regulation by CPEB4 in HSCs during liver injury, the trans-
lational regulation either precedes or dominates over tran-
scriptional control, as activated HSCs in which CPEB4 has
been silenced with shRNAs failed to up-regulate PFKFB3 to
the levels observed in HSCs transfected with control
shRNAs. In addition, CPEB4KO mice subjected to BDL were
unable to up-regulate PFKFB3 expression to the levels
observed in the fibrotic WT mice. Of note, silencing CPEB4
prevents the up-regulation of PFKFB3 observed in patho-
logical conditions (ie, activated LX2 cells, bile duct–ligated
mice), but does not completely abrogate PFKFB3 protein
expression, which is necessary to maintain cellular homeo-
stasis, suggesting the possible benefit of using CPEB4
inhibitors.
The sum of these findings puts the CPEB4-PFKFB3-
dependent axis into the spotlight as a potential target for
antifibrotic strategies. This is relevant because there is an
urgent need for development of novel antifibrotic agents.2,3
Of note, pharmacological PFKFB3 inhibitors such as 3PO are
showing great promise as powerful therapies to target
cancer,42,43 and are already entering phase I clinical trials in
patients with advanced malignancies.44 Furthermore, anti-
glycolytic strategies employing PFKFB3 blockers have been
shown to be particularly beneficial in different cell types
because they only partially inhibit glycolysis (commonly by
40%–50%).10,19 In our studies, 3PO at low doses reduced
glycolysis by 51%, impairing HSC activation without causing
HSC death in vitro. In addition, a partial and daily decrease
of glycolysis sufficed to suppress pathological fibrogenesis
in vivo in bile duct–ligated mice with acceptable tolerability.
This is important because approaches that block glycolysis
completely have been shown to cause adverse (toxic) ef-
fects.10,19 The reason for the partial effect likely relates to
the fact that 3PO blocks an activator of a key enzyme in
glycolysis (PFK1), but has no direct effect on PFK1, which
shares an identical substrate, fructose-6-phosphate.10,18,19
Hence, PFKFB3 blockade has a ceiling level in its ability to
inhibit glycolysis. Our data also provide proof-of-concept
that targeting CPEB4 may be efficacious in treating liver
fibrosis. Of note, we are currently developing different
therapeutic approaches to selectively block the activities of
CPEBs.45,46 These may counteract fibrosis progression by
obstructing the metabolic evolution of activated HSCs
without causing damage to healthy cells, and are therefore
an attractive new strategy in the battle against chronic liver
disease. It is hoped that these CPEB4 inhibitors will make it
to the clinic in the near future.Supplementary Material
Note: To access the supplementary material accompanying
this article, visit the online version of Gastroenterology at
www.gastrojournal.org, and at http://dxdoi.org/10.1053/j.
gastro.2020.03.008.
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